Base de dados : MEDLINE
Pesquisa : D03.383.129.385.650 [Categoria DeCS]
Referências encontradas : 631 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 64 ir para página                         

  1 / 631 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29232310
[Au] Autor:Limosin F; Belhadi D; Comet D; Pacou M; Bouju S; Van Impe K; Guillon P
[Ti] Título:Comparison of Paliperidone Palmitate and Risperidone Long-Acting Injection in Schizophrenic Patients: Results From a Multicenter Retrospective Cohort Study in France.
[So] Source:J Clin Psychopharmacol;38(1):19-26, 2018 Feb.
[Is] ISSN:1533-712X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:PURPOSE/BACKGROUND: The study objective was to compare the impact of being treated by paliperidone palmitate (PP) or risperidone long-acting injection (RLAI) on the length of stay on initial hospitalization, rehospitalization risk, and treatment duration in schizophrenic patients. METHODS: We conducted an observational retrospective cohort study in 43 centers in France, including schizophrenic patients who initiated a treatment by PP or RLAI during initial hospitalization. The follow-up periods started in September 2012 for the RLAI group (median follow-up duration, 233 days) and in June 2013 for the PP group (259 days). Statistical analyses were based on Cox regression models, with propensity score weighting to account for differences in patients' characteristics. FINDINGS/RESULTS: The analysis included 347 patients: 197 in the PP treatment group and 150 in the RLAI group. Compared with patients on RLAI, patients on PP were significantly more likely to have nonpsychiatric comorbidities, to have been on previous antipsychotic therapy, or to have been hospitalized for psychiatric care in the previous year. With regard to length of stay on initial hospitalization, there was no statistically significant difference between both groups (hazard ratio, 1.13 [0.97; 1.31]). Being on PP was associated with similar times to first rehospitalization compared with RLAI (hazard ratio, 0.92 [0.65; 1.30]). IMPLICATIONS/CONCLUSIONS: We observed nonsignificant differences in initial hospitalization duration and time to rehospitalization between PP and RLAI, potentially due to lack of statistical power. A trend was observed in favor of PP with regard to time to treatment discontinuation, although this result was compromised by patients who switched between RLAI and PP.
[Mh] Termos MeSH primário: Antipsicóticos/uso terapêutico
Palmitato de Paliperidona/uso terapêutico
Risperidona/uso terapêutico
Esquizofrenia/tratamento farmacológico
[Mh] Termos MeSH secundário: Adulto
Antipsicóticos/administração & dosagem
Estudos de Coortes
Preparações de Ação Retardada
Feminino
Seguimentos
França
Hospitalização/estatística & dados numéricos
Seres Humanos
Injeções
Tempo de Internação
Masculino
Meia-Idade
Palmitato de Paliperidona/administração & dosagem
Estudos Retrospectivos
Risperidona/administração & dosagem
Resultado do Tratamento
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; MULTICENTER STUDY
[Nm] Nome de substância:
0 (Antipsychotic Agents); 0 (Delayed-Action Preparations); L6UH7ZF8HC (Risperidone); R8P8USM8FR (Paliperidone Palmitate)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180201
[Lr] Data última revisão:
180201
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171213
[St] Status:MEDLINE
[do] DOI:10.1097/JCP.0000000000000827


  2 / 631 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28837593
[Au] Autor:Potkin SG; Loze JY; Forray C; Baker RA; Sapin C; Peters-Strickland T; Beillat M; Nylander AG; Hertel P; Nitschky Schmidt S; Ettrup A; Eramo A; Hansen K; Naber D
[Ad] Endereço:Department of Psychiatry and Human Behavior, University of California, Irvine, California, United States of America.
[Ti] Título:Relationship between response to aripiprazole once-monthly and paliperidone palmitate on work readiness and functioning in schizophrenia: A post-hoc analysis of the QUALIFY study.
[So] Source:PLoS One;12(8):e0183475, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Schizophrenia is a chronic disease with negative impact on patients' employment status and quality of life. This post-hoc analysis uses data from the QUALIFY study to elucidate the relationship between work readiness and health-related quality of life and functioning. QUALIFY was a 28-week, randomized study (NCT01795547) comparing the treatment effectiveness of aripiprazole once-monthly 400 mg and paliperidone palmitate once-monthly using the Heinrichs-Carpenter Quality-of-Life Scale as the primary endpoint. Also, patients' capacity to work and work readiness (Yes/No) was assessed with the Work Readiness Questionnaire. We categorized patients, irrespective of treatment, by work readiness at baseline and week 28: No to Yes (n = 41), Yes to Yes (n = 49), or No at week 28 (n = 118). Quality-of-Life Scale total, domains, and item scores were assessed with a mixed model of repeated measures. Patients who shifted from No to Yes in work readiness showed robust improvements on Quality-of-Life Scale total scores, significantly greater than patients not ready to work at week 28 (least squares mean difference: 11.6±2.6, p<0.0001). Scores on Quality-of-Life Scale instrumental role domain and items therein-occupational role, work functioning, work levels, work satisfaction-significantly improved in patients shifting from No to Yes in work readiness (vs patients No at Week 28). Quality-of-Life Scale total scores also significantly predicted work readiness at week 28. Overall, these results highlight a strong association between improvements in health-related quality of life and work readiness, and suggest that increasing patients' capacity to work is an achievable and meaningful goal in the treatment of impaired functioning in schizophrenia.
[Mh] Termos MeSH primário: Antipsicóticos/uso terapêutico
Aripiprazol/uso terapêutico
Emprego
Palmitato de Paliperidona/uso terapêutico
Esquizofrenia/tratamento farmacológico
[Mh] Termos MeSH secundário: Adulto
Antipsicóticos/administração & dosagem
Aripiprazol/administração & dosagem
Esquema de Medicação
Quimioterapia Combinada
Feminino
Seres Humanos
Masculino
Meia-Idade
Palmitato de Paliperidona/administração & dosagem
Esquizofrenia/fisiopatologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antipsychotic Agents); 82VFR53I78 (Aripiprazole); R8P8USM8FR (Paliperidone Palmitate)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171120
[Lr] Data última revisão:
171120
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170825
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0183475


  3 / 631 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28712616
[Au] Autor:Cameron C; Zummo J; Desai DN; Drake C; Hutton B; Kotb A; Weiden PJ
[Ad] Endereço:Cornerstone Research Group, Inc., Burlington, Ontario, Canada. Electronic address: ccameron@cornerstone-research.com.
[Ti] Título:Aripiprazole Lauroxil Compared with Paliperidone Palmitate in Patients with Schizophrenia: An Indirect Treatment Comparison.
[So] Source:Value Health;20(7):876-885, 2017 Jul - Aug.
[Is] ISSN:1524-4733
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Aripiprazole lauroxil (AL) is a long-acting injectable atypical antipsychotic recently approved for treatment of schizophrenia on the basis of a large-scale trial of two doses of AL versus placebo. There are no direct-comparison studies with paliperidone palmitate (PP; long-acting antipsychotic used most often in acute settings) for the acute psychotic episode. OBJECTIVES: To indirectly compare efficacy and safety of the pivotal AL study with all PP studies meeting indirect comparison criteria. METHODS: Systematic searches of MEDLINE, Embase, Cochrane CENTRAL, PsycINFO, ClinicalTrials.gov, International Clinical Trials Registry Platform, and gray literature were performed to identify randomized controlled trials of PP with similar designs to the AL trial. Bayesian network meta-analysis compared treatments with respect to symptom response and tolerability issues including weight gain, akathisia, parkinsonism, and likelihood of treatment-emergent adverse events. RESULTS: Three appropriate PP studies were identified for indirect comparison. Both doses of AL (441 mg and 882 mg monthly) were used and compared with two efficacious doses of PP (156 mg and 234 mg monthly). All four active-treatment conditions were associated with comparable reductions in acute symptoms (Positive and Negative Syndrome Scale) versus placebo and were of similar magnitude (range of mean difference -8.12 to -12.01, with overlapping 95% credible intervals). Between-group comparisons of active-treatment arms were associated with summary estimates of magnitude near 0. No clinically meaningful differences in selected safety or tolerability parameter incidence were found between active treatments. CONCLUSIONS: These results suggest that both AL and PP are effective for treatment of adults experiencing acute exacerbation of schizophrenia.
[Mh] Termos MeSH primário: Aripiprazol/uso terapêutico
Palmitato de Paliperidona/uso terapêutico
Esquizofrenia/tratamento farmacológico
[Mh] Termos MeSH secundário: Adulto
Antipsicóticos/administração & dosagem
Antipsicóticos/efeitos adversos
Antipsicóticos/uso terapêutico
Aripiprazol/administração & dosagem
Aripiprazol/efeitos adversos
Teorema de Bayes
Relação Dose-Resposta a Droga
Seres Humanos
Palmitato de Paliperidona/administração & dosagem
Palmitato de Paliperidona/efeitos adversos
Escalas de Graduação Psiquiátrica
Ensaios Clínicos Controlados Aleatórios como Assunto
Esquizofrenia/fisiopatologia
Resultado do Tratamento
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; META-ANALYSIS; REVIEW
[Nm] Nome de substância:
0 (Antipsychotic Agents); 82VFR53I78 (Aripiprazole); B786J7A343 (aripiprazole lauroxil); R8P8USM8FR (Paliperidone Palmitate)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170724
[Lr] Data última revisão:
170724
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170718
[St] Status:MEDLINE


  4 / 631 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28699847
[Au] Autor:Schoretsanitis G; Spina E; Hiemke C; de Leon J
[Ad] Endereço:a University Hospital of Psychiatry , Bern , Switzerland.
[Ti] Título:A systematic review and combined analysis of therapeutic drug monitoring studies for long-acting risperidone.
[So] Source:Expert Rev Clin Pharmacol;10(9):965-981, 2017 Sep.
[Is] ISSN:1751-2441
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: This systematic review of therapeutic drug monitoring (TDM) identifies three long-acting injectable (LAI) risperidone formulations. Areas covered: Limited data is available on two formulations (RBP-7000 and in Situ Microparticle), but 20 TDM articles on the microsphere formulation were found. Risperidone TDM includes the serum concentrations of risperidone and its active metabolite, 9-hydroxyrisperidone, used for calculating: 1) the risperidone/9-hydroxyrisperidone (R/9-OH-R) ratio (a measure of CYP2D6; values >1 are indicative of a CYP2D6 poor metabolizer) and 2) the total risperidone concentration-to-dose (C/D) ratio (a measure of risperidone clearance with a normal value around 7 in oral risperidone). The weighted mean R/9-OH-R ratio was 0.48 (approximately twice that of oral risperidone TDM) in a combined analysis from 329 patients in 6 risperidone LAI studies without major confounders. The total C/D ratios from 297 patients in 6 risperidone LAI studies ranged from 7.4 to 9.7 ng/ml/mg/day with a weighted mean of 8.8 ng/ml/mg/day. Expert commentary: Clinicians using TDM for risperidone LAI microsphere formulation need to: 1) consider steady state to be reached ≥ 6 weeks after the first injection, 2) pay attention to a) co-medications with inducers/inhibitors, b) severe inflammations/infections, and c) hepatic/renal impairment, and 3) use Castberg's recommendation to calculate risperidone dosing.
[Mh] Termos MeSH primário: Antipsicóticos/administração & dosagem
Monitoramento de Medicamentos/métodos
Risperidona/administração & dosagem
[Mh] Termos MeSH secundário: Administração Oral
Animais
Antipsicóticos/farmacocinética
Preparações de Ação Retardada
Seres Humanos
Injeções
Microesferas
Palmitato de Paliperidona/farmacocinética
Risperidona/farmacocinética
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Antipsychotic Agents); 0 (Delayed-Action Preparations); L6UH7ZF8HC (Risperidone); R8P8USM8FR (Paliperidone Palmitate)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170904
[Lr] Data última revisão:
170904
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170713
[St] Status:MEDLINE
[do] DOI:10.1080/17512433.2017.1345623


  5 / 631 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28675307
[Au] Autor:Macaluso M; Oliver H; Sohail Z
[Ad] Endereço:a Psychiatry and Behavioral Sciences , University of Kansas School of Medicine , Wichita , KS , USA.
[Ti] Título:Pharmacokinetic drug evaluation of paliperidone in the treatment of schizoaffective disorder.
[So] Source:Expert Opin Drug Metab Toxicol;13(8):871-879, 2017 Aug.
[Is] ISSN:1744-7607
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: This paper reviews the pharmacokinetics, receptor binding, clinical efficacy and safety of paliperidone in the treatment of patients with schizoaffective disorder. Areas covered: We reviewed the literature using keywords 'paliperidone', 'schizoaffective disorder' and 'clinical trials' with a focus on seminal data papers and information that is clinically relevant to the treatment of schizoaffective disorder. The purpose of this paper is to provide a clinically oriented review of the pharmacokinetic and pharmacodynamic properties of paliperidone including receptor binding, clinical efficacy, safety and tolerability. Expert opinion: Paliperidone is currently the only medication FDA approved specifically for the treatment of schizoaffective disorder. Paliperidone is an active metabolite of risperidone, is minimally metabolized in the liver and is primarily known to be cleared through the kidneys. For this reason, paliperidone could be considered for some patients with schizoaffective disorder who also have hepatic impairment. After correcting for the reduced protein binding that is characteristic of hepatically impaired patients, the Cmax was 12% lower than in healthy subjects while the AUC and CL/F were comparable [14]. In addition, the availability of long acting injectable formulations may be useful for patients who are non-adherent with oral medications. The cost of paliperidone may be a disadvantage.
[Mh] Termos MeSH primário: Antipsicóticos/administração & dosagem
Palmitato de Paliperidona/administração & dosagem
Transtornos Psicóticos/tratamento farmacológico
[Mh] Termos MeSH secundário: Animais
Antipsicóticos/efeitos adversos
Antipsicóticos/farmacocinética
Área Sob a Curva
Preparações de Ação Retardada
Seres Humanos
Fígado/metabolismo
Hepatopatias/metabolismo
Palmitato de Paliperidona/efeitos adversos
Palmitato de Paliperidona/farmacocinética
Ligação Proteica
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Antipsychotic Agents); 0 (Delayed-Action Preparations); R8P8USM8FR (Paliperidone Palmitate)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170807
[Lr] Data última revisão:
170807
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170705
[St] Status:MEDLINE
[do] DOI:10.1080/17425255.2017.1351546


  6 / 631 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Registro de Ensaios Clínicos
Registro de Ensaios Clínicos
Registro de Ensaios Clínicos
Texto completo
[PMID]:28640988
[Au] Autor:Weiden PJ; Kim E; Bermak J; Turkoz I; Gopal S; Berwaerts J
[Ad] Endereço:Uptown Research Institute, LLC, Chicago, Illinois, USA.
[Ti] Título:Does Half-Life Matter After Antipsychotic Discontinuation? A Relapse Comparison in Schizophrenia With 3 Different Formulations of Paliperidone.
[So] Source:J Clin Psychiatry;78(7):e813-e820, 2017 Jul.
[Is] ISSN:1555-2101
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: To evaluate the effect of 1 oral and 2 distinct long-acting injectable (LAI) formulations of the same antipsychotic on times to relapse following medication discontinuation. METHODS: Data were drawn from 3 similarly designed, multicenter, double-blind, placebo-controlled, randomized-withdrawal studies of paliperidone in adults with a schizophrenia diagnosis (according to DSM-IV criteria for ≥ 1 year before screening): once-daily extended-release oral paliperidone (ORAL paliperidone), once-monthly paliperidone palmitate (PP1M), and once-every-3-months paliperidone palmitate (PP3M). In a post hoc analysis, we compared median time to relapse across the treatment-withdrawal arms of the 3 studies using final analysis datasets. Time to relapse in the withdrawal arm of each study was examined using log-rank tests and Cox proportional hazards models. RESULTS: Four hundred forty-nine patients were withdrawn from 3 paliperidone formulations: 101 from ORAL paliperidone, 203 from PP1M, and 145 from PP3M. Postwithdrawal median (95% confidence interval [CI]) days to relapse were 58 days (42-114 days) for ORAL paliperidone, 172 days (134-222 days) for PP1M, and 395 days (274 days-not reached) for PP3M (P < .0001, pairwise comparisons). Relapse risk was significantly lower (P < .001) for patients who withdrew from either PP formulation relative to ORAL paliperidone and additionally for patients who withdrew from PP3M relative to PP1M. CONCLUSIONS: Results demonstrate that 50% of patients who withdrew treatment from ORAL paliperidone, PP1M, or PP3M remained relapse free for approximately 2 months, 6 months, and 13 months, respectively. This may be relevant for risk mitigation strategies in schizophrenia, a condition in which interruptions in maintenance antipsychotic treatment are commonplace and unpredictable. LAI antipsychotic formulations may provide substantial delays over oral equivalents in times to relapse when patients discontinue therapy. TRIAL REGISTRATION: ClinicalTrials.gov identifiers: NCT00086320, NCT00111189, and NCT01529515.
[Mh] Termos MeSH primário: Palmitato de Paliperidona/administração & dosagem
Palmitato de Paliperidona/farmacocinética
Esquizofrenia/sangue
Esquizofrenia/tratamento farmacológico
Psicologia do Esquizofrênico
Síndrome de Abstinência a Substâncias/sangue
[Mh] Termos MeSH secundário: Administração Oral
Adulto
Preparações de Ação Retardada
Método Duplo-Cego
Feminino
Meia-Vida
Seres Humanos
Injeções Intramusculares
Masculino
Palmitato de Paliperidona/efeitos adversos
Recidiva
Medição de Risco
Relação Estrutura-Atividade
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Delayed-Action Preparations); R8P8USM8FR (Paliperidone Palmitate)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170921
[Lr] Data última revisão:
170921
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170623
[Cl] Clinical Trial:ClinicalTrial
[St] Status:MEDLINE


  7 / 631 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28628827
[Au] Autor:Patel H; Kukol A
[Ad] Endereço:School of Life and Medical Sciences, University of Hertfordshire, Hatfield AL10 9AB, United Kingdom. Electronic address: h.patel28@herts.ac.uk.
[Ti] Título:Evolutionary conservation of influenza A PB2 sequences reveals potential target sites for small molecule inhibitors.
[So] Source:Virology;509:112-120, 2017 Sep.
[Is] ISSN:1096-0341
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The influenza A basic polymerase protein 2 (PB2) functions as part of a heterotrimer to replicate the viral RNA genome. To investigate novel PB2 antiviral target sites, this work identified evolutionary conserved regions across the PB2 protein sequence amongst all sub-types and hosts, as well as ligand binding hot spots which overlap with highly conserved areas. Fifteen binding sites were predicted in different PB2 domains; some of which reside in areas of unknown function. Virtual screening of ~50,000 drug-like compounds showed binding affinities of up to -10.3kcal/mol. The highest affinity molecules were found to interact with conserved residues including Gln138, Gly222, Ile529, Asn540 and Thr530. A library containing 1738 FDA approved drugs was screened additionally and revealed Paliperidone as a top hit with a binding affinity of -10kcal/mol. Predicted ligands are ideal leads for new antivirals as they were targeted to evolutionary conserved binding sites.
[Mh] Termos MeSH primário: Antivirais/isolamento & purificação
Sequência Conservada
Descoberta de Drogas/métodos
Palmitato de Paliperidona/isolamento & purificação
RNA Replicase/genética
Proteínas Virais/genética
[Mh] Termos MeSH secundário: Sítios de Ligação
Avaliação Pré-Clínica de Medicamentos
Seres Humanos
Simulação de Dinâmica Molecular
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antiviral Agents); 0 (PB2 protein, Influenzavirus A); 0 (Viral Proteins); EC 2.7.7.48 (RNA Replicase); R8P8USM8FR (Paliperidone Palmitate)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170721
[Lr] Data última revisão:
170721
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170620
[St] Status:MEDLINE


  8 / 631 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28614404
[Au] Autor:Decuypere F; Sermon J; Geerts P; Denee TR; De Vos C; Malfait B; Lamotte M; Mulder CL
[Ad] Endereço:Commercial Services, QuintilesIMS, Zaventem, Belgium.
[Ti] Título:Treatment continuation of four long-acting antipsychotic medications in the Netherlands and Belgium: A retrospective database study.
[So] Source:PLoS One;12(6):e0179049, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Achieving greater continuation of treatment is a key element to improve treatment outcomes in schizophrenia patients. However, reported treatment continuation can differ markedly depending on the study design. In a retrospective setting, treatment continuation remains overall poor among patients using antipsychotics. This study aimed to document the difference in treatment continuation between four long-acting injectable antipsychotics based on the QuintilesIMS LRx databases, national, longitudinal, panel based prescription databases of retail pharmacies, in the Netherlands and Belgium. Paliperidone palmitate once monthly, risperidone microspheres, haloperidol decanoate, and olanzapine pamoate were studied. This study demonstrated significantly higher treatment continuation of paliperidone palmitate once monthly compared to risperidone microspheres (p-value<0,01) and haloperidol decanoate (p-value<0,01) in both countries, a significantly higher treatment continuation of paliperidone palmitate once monthly compared to olanzapine pamoate in the Netherlands (p-value<0,01), and a general trend towards better treatment continuation versus olanzapine pamoate in Belgium. Analysing the subgroup of patients without previous exposure to long-acting antipsychotic treatment revealed the positive impact of previous exposure on treatment continuation with a subsequent long acting treatment. Additionally, the probability of restarting the index therapy was higher among patients treated with paliperidone palmitate once monthly compared to patients treated with risperidone microspheres and haloperidol decanoate. The data source used and the methodology defined ensured for the first time a comparison of treatment continuation in a non-interventional study design for the four long-acting injectable antipsychotics studied.
[Mh] Termos MeSH primário: Antipsicóticos/administração & dosagem
Preparações de Ação Retardada/administração & dosagem
Adesão à Medicação/estatística & dados numéricos
Esquizofrenia/tratamento farmacológico
[Mh] Termos MeSH secundário: Adulto
Antipsicóticos/uso terapêutico
Bélgica
Benzodiazepinas/administração & dosagem
Benzodiazepinas/uso terapêutico
Preparações de Ação Retardada/uso terapêutico
Esquema de Medicação
Feminino
Haloperidol/administração & dosagem
Haloperidol/análogos & derivados
Haloperidol/uso terapêutico
Seres Humanos
Países Baixos
Palmitato de Paliperidona/administração & dosagem
Palmitato de Paliperidona/uso terapêutico
Estudos Retrospectivos
Risperidona/administração & dosagem
Risperidona/uso terapêutico
Resultado do Tratamento
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antipsychotic Agents); 0 (Delayed-Action Preparations); 12794-10-4 (Benzodiazepines); AC20PJ4101 (haloperidol decanoate); J6292F8L3D (Haloperidol); L6UH7ZF8HC (Risperidone); N7U69T4SZR (olanzapine); R8P8USM8FR (Paliperidone Palmitate)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170915
[Lr] Data última revisão:
170915
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170615
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0179049


  9 / 631 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28374699
[Au] Autor:D'yakov IN; Zyryanov SK
[Ad] Endereço:Mechnikov Research Institute of Vaccines and Sera.
[Ti] Título:[Comparative evaluation of clinical and economic efficiency of paliperidone in various dosage forms used in patients with schizophrenia].
[Ti] Título:Sravnitel'naya otsenka kliniko-ekonomicheskoi effektivnosti primeneniya razlichnykh lekarstvennykh form paliperidona pri lechenii patsientov s shizofreniei..
[So] Source:Zh Nevrol Psikhiatr Im S S Korsakova;117(2):85-92, 2017.
[Is] ISSN:1997-7298
[Cp] País de publicação:Russia (Federation)
[La] Idioma:rus
[Ab] Resumo:AIM: To evaluate clinical and economic efficacy of schizophrenia treatment with three forms of paliperidone (peroral form, intramuscular injections once a month and once in three month). MATERIAL AND METHODS: Pharmacoeconomic analysis based on the results of earlier foreign randomized clinical studies on paliperidone in treatment of schizophrenia was carried out. Indirect comparison of different medication forms of paliperidone compared to placebo was performed. The analysis of costs was based on a Markov model built for the study. Two categories of costs: costs of pharmacological treatment with paliperidone and costs of disease exacerbation due to the violation of treatment regimen were considered. To assess pharmacoeconomic efficacy of paliperidone, a cost-benefit analysis with calculation of cost utility ratio (CUR) and incremental cost utility ratio (ICUR) was used. RESULTS AND CONCLUSION: In view of the influence on the budget, all forms of paliperidone have similar pharmacoeconomic efficacy with the advantage of prolonged release injectable (depot) forms that increase patient's adherence to treatment. As a result, CUR of injectable forms was lower compared to that of the peroral form by 11,1 and 46,3% of month and 3-month forms, respectively. ICUR for paliperidone used once in 3 month (trevicta) was more effective compared to paliperidone used monthly (xeplion). It has been concluded that paliperidone for prolonged release injections used once in 3 month is most pharmacoeconomically effective.
[Mh] Termos MeSH primário: Antipsicóticos/administração & dosagem
Antipsicóticos/economia
Palmitato de Paliperidona/administração & dosagem
Palmitato de Paliperidona/economia
Esquizofrenia/tratamento farmacológico
[Mh] Termos MeSH secundário: Administração Oral
Análise Custo-Benefício
Preparações de Ação Retardada/administração & dosagem
Preparações de Ação Retardada/economia
Esquema de Medicação
Seres Humanos
Injeções Intramusculares
Ensaios Clínicos Controlados Aleatórios como Assunto
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antipsychotic Agents); 0 (Delayed-Action Preparations); R8P8USM8FR (Paliperidone Palmitate)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170810
[Lr] Data última revisão:
170810
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170405
[St] Status:MEDLINE
[do] DOI:10.17116/jnevro20171172185-92


  10 / 631 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28346773
[Au] Autor:Gaviria AM; Franco J; Rico G; Muntané G; Sáez C; Sánchez-Gistau V; de Pablo J; Vilella E
[Ad] Endereço:Hospital Universitari Institut Pere Mata, IISPV, Universitat Rovira i Virgili, CIBERSAM, Reus, Spain.
[Ti] Título:Noninterventional, Naturalistic, Retrospective Study to Describe Prescription Patterns of Long-Acting Injectable Antipsychotics and the Impact of Introducing a New Atypical Antipsychotic in the Spanish Province of Tarragona Catchment Area.
[So] Source:Prim Care Companion CNS Disord;19(2), 2017 03 23.
[Is] ISSN:2155-7780
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Background: We studied the patterns and predictors of long-acting injectable (LAI) antipsychotic (AP) use in the treatment of schizophrenia and the effect of introducing a new LAI (paliperidone palmitate [paliperidone-LAI]) in the Spanish province of Tarragona. Methods: This noninterventional, naturalistic, retrospective study included electronic medical record data from a large population-based database of 1,646 patients who were diagnosed with schizophrenia according to ICD-10 criteria and treated between January 2011 and December 2013. Results: During the study period, 42.0% of patients were treated with an LAI AP. The most frequently prescribed initial LAI was risperidone (52.0% of patients). A total of 23% of patients initially treated with an oral AP were switched to an LAI AP, a change that was associated with younger age (P = .001), undifferentiated schizophrenia (P = .015), substance abuse (P < .001), and neuropsychiatric comedication with the following agents: anticonvulsants (P = .004), anticholinergics (P < .001), and hypnotics/sedatives (P = .03). The change from an oral AP to paliperidone-LAI was predicted by younger age (P < .001). Overall, 27.5% of patients switched to another LAI AP, and paliperidone-LAI was the preferred option in 64.7% of cases. The most frequent change involved patients taking risperidone-LAI, many of whom transitioned to paliperidone-LAI (85.0% of cases), particularly patients with a disease duration > 5 years (P = .019). Conclusions: There was a progressive increase in the use of LAI formulations in our catchment area. These agents were preferentially prescribed to patients with chronic disease and a history of substance abuse, as well as patients receiving neuropsychiatric comedication. One-month LAI formulations were commonly used in young patients.
[Mh] Termos MeSH primário: Antipsicóticos/administração & dosagem
Padrões de Prática Médica
Esquizofrenia/tratamento farmacológico
[Mh] Termos MeSH secundário: Adulto
Área Programática (Saúde)
Comorbidade
Bases de Dados Factuais
Preparações de Ação Retardada/administração & dosagem
Substituição de Medicamentos/estatística & dados numéricos
Registros Eletrônicos de Saúde
Feminino
Seres Humanos
Modelos Logísticos
Masculino
Meia-Idade
Palmitato de Paliperidona/administração & dosagem
Estudos Retrospectivos
Esquizofrenia/diagnóstico
Espanha
Análise de Sobrevida
Fatores de Tempo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antipsychotic Agents); 0 (Delayed-Action Preparations); R8P8USM8FR (Paliperidone Palmitate)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170407
[Lr] Data última revisão:
170407
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170328
[St] Status:MEDLINE
[do] DOI:10.4088/PCC.16m02044



página 1 de 64 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde